肿瘤细胞治疗研究
英文原题：Breaking barriers in gynecologic malignancies with adoptive cell transfers and nanomedicine.
Breaking barriers in gynecologic malignancies with adoptive cell transfers and nanomedicine.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
妇科癌症仍然是治疗上具有挑战性的恶性肿瘤，自20世纪70年代引入铂类化疗以来，生存结局改善甚微。这些肿瘤的特征是致密的细胞外基质、异质性免疫浸润和免疫抑制微环境，限制了标准疗法的成功。过继细胞转移（ACT）在克服这些障碍方面显示出前景，但其在妇科肿瘤学中的发展落后于其他癌症。本视角文章概述了导致这一差距的因素、当前的ACT方法，包括TIL（肿瘤浸润淋巴细胞）、T细胞受体工程化T细胞和嵌合抗原受体细胞，并评估了它们在卵巢癌、子宫内膜癌和宫颈癌中的相关性。我们重点介绍了将免疫细胞运输与旨在改善肿瘤内定位、滞留和控释药物的生物材料相结合的新兴策略。我们考虑了每种方法的相对优势和局限性，并为开发这些技术以重塑妇科癌症的临床治疗范式提供了实用考量。
Gynecologic cancers remain challenging malignancies to treat, with little improvement in survival outcomes since the introduction of platinum-based chemotherapy in the 1970s. These tumors are characterized by dense extracellular matrices, heterogeneous immune infiltrates, and immunosuppressive microenvironments that limit the success of standard therapies.
Adoptive cell transfers (ACTs) have shown promise in overcoming these barriers, yet their development in gynecologic oncology lags behind that of other cancers. This perspective outlines factors contributing to this gap, current ACT approaches, including tumor-infiltrating lymphocytes, T-cell receptor-engineered T-cells, and chimeric antigen receptor cells, and evaluates their relevance in ovarian, endometrial, and cervical cancers.
We highlight emergent strategies that integrate immune cell trafficking with biomaterials designed to improve localization, retention, and controlled drug release within tumors.
We consider the relative advantages and limitations of each approach and offer practical considerations for developing these technologies to reshape clinical treatment paradigms for gynecologic cancers.
MEMBER ACCOUNT
登录成功会直接打开下一页。
